• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Aurobindo Pharma Ltd.
    11 Apr 2025
    1093.30
    0.67%
    Aurobindo Pharma's US Plant Gets 11 FDA Observations
    Aurobindo Pharma's US Plant Gets 11 FDA Observations
    NDTV Profit
    The inspection took place from March 24 to April 10, 2025.
    Copy LinkShare onShare on Share on Share on
    Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1080.4
    logo
    Sun Pharmaceutical Industries Ltd.
    11 Apr 2025
    1631.20
    -0.31%
    Sun Pharma stock up 2.4% as roads cleared for launch of alopecia drug
    Business Standard
    According to market estimates, Leqselvi is projected to contribute $90 million to Sun Pharma's sales in FY26, and $125 million in FY27
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical Industries Ltd. is trading above its 50 day SMA of 1626.3
    Here's why Sun Pharma share price advanced 5% in trade on April 11; details
    Business Standard | 11 Apr 2025
    logo
    Laurus Labs Ltd.
    11 Apr 2025
    864.40
    -0.87%
    Laurus Labs surges 8%, stock records sharpest intraday gain since Jan 30
    Business Standard
    The pipeline is expected to be robust, and the company expects to do well in the human health and animal health CDMO divisions in Q4FY25E and in FY26E, according to analysts.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd. has gained 50.47% in the last 6 Months
    logo
    Morepen Laboratories Ltd.
    11 Apr 2025
    49.23
    0.86%
    Morepen to hire 1,000 medical representatives to boost formulations biz
    Business Standard
    Morepen Laboratories on Friday said it will add more than 1,000 medical representatives over the next three years, with over 200 team members expected to join in FY26 alone. The company aims to strengthen its formulations business in the market through new hirings. "This expansion represents a pivotal moment in Morepen's journey as we sharpen our focus on the expanding domestic finished dosage market," Morepen Laboratories Chairman and MD Sushil Suri said in a statement. With significant increase in the sales force and enhanced reach to doctors, pharmacies, and patients, the drugmaker is setting the stage for getting a bigger pie in the Indian pharmaceutical market valued at Rs 2.38 lakh crore, yielding higher gross margins and better returns for stakeholders in the long run, he added. Currently, Morepen's formulation business stands around Rs 325 crore, and the company is targeting to touch Rs 1,000 crore in the next five years. This goal will be supported by an aggressive expans
    Copy LinkShare onShare on Share on Share on
    Morepen Laboratories Ltd. is trading below all available SMAs
    logo
    Cipla Ltd.
    11 Apr 2025
    1517.70
    0.31%
    Cipla gets USFDA nod to market generic version of cancer drug Abraxane
    Business Standard
    Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for paclitaxel protein-bound particles for injectable suspension (albumin-bound), 100 mg/vial, single-dose vial, Cipla said in a regulatory filing. Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial. Protein-bound paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in the first half of the current fiscal year in the US, the Mumbai-based drugmaker said. Shares of the company were trading 2.73 per cent up at Rs 1,454.90 apiece on the BSE.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.
    Cipla gets USFDA nod for generic cancer drug
    Business Line | 11 Apr 2025 1 more
    Cipla share price jumps 5% as USFDA okays cancer drug Paclitaxel
    Business Standard | 11 Apr 2025
    logo
    Aurobindo Pharma Ltd.
    11 Apr 2025
    1093.30
    0.67%
    Aurobindo Pharma shares jump 4% as arm completes phase1 trial for bone drug
    Business Standard
    Denosumab works by specifically targeting the RANK ligand (RANKL), a critical protein in the lifecycle of osteoclasts, the cells that break down bone
    Copy LinkShare onShare on Share on Share on
    Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings
    logo
    Granules India Ltd.
    10 Apr 2025
    557.30
    2.70%
    Granules India completes acquisition of Swiss CDMO Senn Chemicals AG
    Business Standard
    The acquisition was executed through Granules' wholly owned subsidiary, Granules Peptides
    Copy LinkShare onShare on Share on Share on
    Geojit BNP Paribas increased Accumulate price target of Granules India Ltd. to 630.0 on 18 Sep, 2025.
    Granules India completes acquisition of Senn Chemicals
    Business Line | 10 Apr 2025
    logo
    Novartis India Ltd.
    10 Apr 2025
    896.15
    1.50%
    Trump's tariffs, market volatility delay marquee M&A transactions in India
    Business Standard
    Bankers say high-profile deals, including those involving the sale of AkzoNobel India, Novartis India, and HDB Financial Services, are now on pause as buyers seek more time to navigate valuation fog
    Copy LinkShare onShare on Share on Share on
    Novartis India Ltd. is trading at high day volume of 11641.00000.
    logo
    Sun Pharmaceutical Industries Ltd.
    10 Apr 2025
    1631.20
    -0.31%
    US court clears Sun Pharma to launch Leqselvi for alopecia areata treatment
    Business Standard
    Sun Pharma is now preparing to launch the drug in US markets after facing legal issues since November 2024
    Copy LinkShare onShare on Share on Share on
    Sun Pharmaceutical I.. has an average target of 2050.25 from 8 brokers.
    logo
    Sun Pharmaceutical Industries Ltd.
    10 Apr 2025
    1631.20
    -0.31%
    Sun Pharmasays US appeals court removes injunction on Leqselvilaunch
    Business Line
    The pharma stock closed 2 per cent lower on Wednesday. Trading operations will resume on April 11.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 1351 to 1326 in Jun 2025 qtr
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • DSM Fresh Foods
    • Greenleaf Envirotech
    • NSB BPO Solutions
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd (RA SEBI Reg No: INH000022507)